List of CAR-T Immunotherapy Companies in India - 5

CrisprBits was started by entrepreneurs and scientists with extensive industry and academic experience, including in the biological sciences. We have prior experience in developing diagnostic solutions, precision medicine and clinical-research solutions that are used by pharmaceutical and biotechnology companies in India and around the world. We are motivated by three guiding principles: using deep science to deliver high quality products; adhering to the highest ethical standards, including in the choice of products we offer; and developing an organization that draws exceptional individuals with diverse backgrounds and affinities. We have offices in Delhi and Bengaluru. Our lab is located in C-CAMP, a premier incubator for biotechnology innovation in Bengaluru.

East Ocyon Bio Private Limited: Advancing Cell and Gene Therapy East Ocean Bio Private Limited is a leading cell and gene therapy company headquartered in India. We are committed to advancing the development and delivery of cell and gene therapies to patients around the world. Our team of experienced scientists and clinicians is dedicated to developing innovative cell and gene therapies that can address unmet medical needs. We are dedicated to realizing the potential of natural killer (NK) cells for the treatment of cancer. Our proprietary technology is designed to harness the power of these important pathogen-fighting immune cells and is uniquely capable of enhancing their ability to search and destroy tumor cells.

Gennova Biopharmaceuticals Ltd. is a biotechnology company based in Pune, Maharashtra, India. The company specializes in the research, development, production, and commercialization of biotherapeutics and vaccines aimed at treating life-threatening diseases in areas such as cardiovascular, neurology, nephrology, and oncology. Gennova employs advanced recombinant DNA technologies and innovative bio-manufacturing practices to create effective biotherapeutic solutions. The company utilizes various expression platforms, including bacterial, mammalian, and yeast-based systems, to produce its recombinant products. Gennova has successfully commercialized seven products, including Tenectase, a biosimilar for treating Acute Ischemic Stroke, and HAMSYL, a treatment for acute lymphoblastic lymphoma offered at a lower price point for better accessibility. With a strong focus on research and development, Gennova is recognized as a preferred partner in the vaccine sector for research and cGMP manufacturing. The company employs around 598 people and has reported a revenue of $2.8 million, positioning itself as a notable player in the Indian biotechnology landscape.

A pioneering clinical stage startup company leading the Cell & Gene therapy revolution and are committed to bringing breakthrough cancer treatment to patients in India, making it accessible & affordable.

ImmunoACT, also known as ImmunoAdoptive Cell Therapy Private Limited, is an Indian biotechnology company specializing in cell and gene therapies. Founded by Dr. Rahul Purwar and Dr. Atharva Karulkar, the company aims to provide affordable access to innovative autologous Chimeric Antigen Receptor (CAR) T-cell therapies. It originated as a spin-off from the Indian Institute of Technology Bombay and is incubated at the Society for Innovation and Entrepreneurship. The company focuses on translational research and development in cell and gene therapy. One of its notable products is NexCAR19, a cost-effective version of CAR-T therapy aimed at treating leukemia and lymphoma. ImmunoACT is committed to expanding its impact through partnerships, such as its collaboration with Caring Cross to commercialize TriCAR T-cell immunotherapy. The company strives to make advanced therapies more accessible to patients in India and beyond.